Abstract Background Pancreatic adenocarcinomas (PAs) have very poor prognoses even
when surgery is possible. Currently, there are no tissular biomarkers to predict long-term …

Pancreatic cancer is currently one of the deadliest solid malignancies and pancreatic ductal
adenocarcinoma (PDAC) is the most common type of pancreatic cancer. In the past decade …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal
cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection …

Simple Summary Pancreatic cancer is a clinically heterogeneous disease, and treatment
leads to different outcomes for people with similar diagnoses. Identifying patients who may …

Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is
no blood test for early detection and diagnosis of this disease. Several research groups …

Background A reliable biomarker to detect pancreatic ductal adenocarcinoma (PDAC)
continues to be elusive. With employing metabolomics we hypothesize that a broader …

Background Early detection of pancreatic ductal adenocarcinoma (PDAC) may improve the
prognosis of patients. This study was to identify metabolic features of PDAC and to discover …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by high heterogeneity, and the
postoperative prognosis of different patients often varies greatly. Therefore, the classification …

Purpose pancreatic adenocarcinoma is the fourth leading cause of cancer related deaths
due to its aggressive behavior and poor clinical outcome. There is a considerable variability …

Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with
poor prognosis in part due to the lack of early detection and screening methods …